Related Experiment Video
Updated: May 7, 2026

Modeling Encephalopathy of Prematurity Using Prenatal Hypoxia-ischemia with Intra-amniotic Lipopolysaccharide in Rats
Published on: November 20, 2015
Late preterm infants: near term but still in a critical developmental time period
Amir Kugelman1, Andrew A Colin
1Bnai Zion Medical Center, Department of Neonatology and Pediatric Pulmonary Unit, 47 Golomb Street, Haifa, 31048, Israel. amirkug@gmail.com.
Insights
Late preterm infants, born between 34-36 weeks, face higher risks for long-term health issues. Understanding critical developmental periods is key to improving outcomes for these vulnerable infants.
Area of Science:
- Neonatal Medicine
- Developmental Pediatrics
- Perinatal Health
Background:
- Late preterm (LP) infants (34-36 weeks gestation) are not fully mature.
- The final weeks of gestation are critical for fetal brain and lung development.
- LP infants exhibit increased risks for serious morbidity and mortality compared to term infants.
Purpose of the Study:
- To review long-term neurodevelopmental and respiratory outcomes in late preterm infants.
- To identify prenatal, neonatal, developmental, and environmental factors contributing to increased morbidities.
- To explore the parallel development of pulmonary and neurological systems.
Main Methods:
- Literature review focusing on neurodevelopmental and respiratory outcomes.
- Analysis of factors influencing fetal and neonatal maturation.
- Examination of the critical developmental time period impacting infant health.
Main Results:
- Accumulating evidence indicates higher risks for health complications in LP infants.
- A threefold higher infant mortality rate is observed in LP infants compared to term infants.
- Disruptions in the intrauterine environment may lead to long-term consequences in pulmonary and neurological systems.
Conclusions:
- Late preterm birth poses significant long-term risks, necessitating careful monitoring.
- The critical developmental period is a potential common pathway for adverse outcomes.
- Understanding these risks informs perinatal and neonatal care strategies for infants and children.
Abstract:
Late preterm (LP) infants are defined as those born at 34-0/7 to 36-6/7 weeks' gestational age. LP infants were previously referred to as near term infants. The change in terminology resulted from the understanding that these infants are not fully mature and that the last 6 weeks of gestation represent a critical period of growth and development of the fetal brain and lungs, and of other systems. There is accumulating evidence of higher risks for health complications in these infants, including serious morbidity and a threefold higher infant mortality rate compared with term infants. This information is of critical importance because of its scientific merits and practical implications. However, it warrants a critical and balanced review, given the apparent overall uncomplicated outcome for the majority of LP infants. Others reviewed the characteristics of LP infants that predispose them to a higher risk of morbidity at the neonatal period. This review focuses on the long-term neurodevelopmental and respiratory outcomes, with the main aim to suggest putative prenatal, neonatal, developmental, and environmental causes for these increased morbidities. It demonstrates parallelism in the trajectories of pulmonary and neurologic development and evolution as a model for fetal and neonatal maturation. These may suggest the critical developmental time period as the common pathway that leads to the outcomes. Disruption in this pathway with potential long-term consequences in both systems may occur if the intrauterine milieu is disturbed. Finally, the review addresses the practical implications on perinatal and neonatal care during infancy and childhood.
Related Concept Videos
The Nativist Approach
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
Pharmacokinetics in Pediatric Patients: Drug Metabolism
Piaget's Stage 1 of Cognitive Development
Exploration...
Neurulation
Pharmacokinetics in Pediatric Patients: Drug Excretion

